The Third Pillar of Precision Medicine — Precision Delivery

Abstract

Precision Medicine is thought of as having two main pillars: Precision Diagnosis and Precision Therapy. However, for Precision Medicine to reach its full potential, a third pillar is needed that we propose to call Precision Delivery. In the laboratory, many therapies show great efficacy when tested directly with target cells. However, upon clinical translation, they are often given via intravenous or oral administration, resulting in their systemic distribution. To ensure therapies reach target sites at the correct therapeutic levels, they are often given at higher concentrations. However, this can be associated with off-target effects, side-effects, and unwanted interactions. Delivery strategies can help mitigate this by “spatially re-coupling” therapies in vivo with target cells. This review explains the concept of Precision Delivery, which can be thought of as three interconnected, but independent, modules: targeted delivery, microenvironment modulation, and cellular interactions. While locoregional approaches directly deliver therapies into target tissues through endovascular, endoluminal, percutaneous, and implantation techniques, microenvironment modulation technologies facilitate the movement of therapies across biological barriers and through tissue matrices, so optimized therapies can reach and interact with target cells. We highlight new innovations driving advances in Precision Delivery, while also discussing the considerations and challenges that Precision Delivery faces as it becomes increasingly integrated into treatment workflows.

Keywords

cellular interactions / locoregional delivery / microenvironment modulation / precision delivery / precision medicine / targeted delivery

References

[1] S. S. Gambhir, T. J. Ge, O. Vermesh, R. Spitler, and G. E. Gold, “Continuous Health Monitoring: An Opportunity for Precision Health,” Science Translational Medicine (2021): 13.

[2] D. Ho, S. R. Quake, E. R. McCabe, et al., “Enabling Technologies for Personalized and Precision Medicine,” Trends in Biotechnology 38 (2020): 497-518.

[3] A. A. Seyhan, “Lost in Translation: The Valley of Death Across Preclinical and Clinical Divide - identification of Problems and Overcoming Obstacles,” Translational Medicine Communications 4 (2019): 18.

[4] M. Ducreux, G. Abou-Alfa, T. Bekaii-Saab, et al., “The Management of Hepatocellular Carcinoma. Current Expert Opinion and Recommendations Derived From the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022,” ESMO Open 8 (2023): 101567.

[5] C. Laface, M. Laforgia, P. Molinari, et al., “Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art,” Cancers (Basel) (2021): 13.

[6] S. Guadagni, O. Zoras, G. Fiorentini, et al., “A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients,” Journal of Surgical Research 268 (2021): 737-747.

[7] C. Li, W. Guo, S. Chen, J. Xu, F. Li, and L. Wang, “Comparison of Regional Arterial Chemotherapy and Systemic Intravenous Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-analysis,” Journal of Pancreatology 5 (2022): 49-57.

[8] K. Mitsumori, K. Sato, and T. Kato, “[Intra-arterial chemotherapy in urological cancer],” Gan to kagaku ryoho Cancer & chemotherapy 29 (2002): 197-203.

[9] A. Homma, R. Onimaru, K. Matsuura, K. T. Robbins, and M. Fujii, “Intra-arterial Chemoradiotherapy for Head and Neck Cancer,” Japanese Journal of Clinical Oncology 46 (2016): 4-12.

[10] P. Kolyvas, A. Mir, T. Stirrat, et al., “Advanced Interventional Treatments in Retinoblastoma Management: A Comprehensive Review,” Cardiovascular and Interventional Radiology 47 (2024): 407-415.

[11] S. Patel, A. Hasanain, A. Fang, et al., “Intra-arterial Locoregional Therapies for Intrahepatic Cholangiocarcinoma,” Expert Review of Gastroenterology & Hepatology 18 (2024): 505-519.

[12] M. Pinkiewicz, M. Pinkiewicz, J. Walecki, and M. Zawadzki, “A Systematic Review on Intra-arterial Cerebral Infusions of Chemotherapeutics in the Treatment of Glioblastoma Multiforme: The state-of-the-art,” Frontiers in Oncology 12 (2022): 950167.

[13] J. Liu, H. Cabral, and P. Mi, “Nanocarriers Address Intracellular Barriers for Efficient Drug Delivery, Overcoming Drug Resistance, Subcellular Targeting and Controlled Release,” Advanced Drug Delivery Reviews 207 (2024): 115239.

[14] S. Levitte, R. Yarani, and A. Ganguly, “Case Series of Precision Delivery of Methylprednisolone in Pediatric Inflammatory Bowel Disease: Feasibility, Clinical Outcomes, and Identification of a Vasculitic Transcriptional Program,” Journal of Clinical Medicine 12 (2023).

[15] S. Levitte, A. A. Guevara-Tique, A. Ganguly, et al., “Precision Delivery of Therapeutics to the Intestine: A Case Series of Superselective Steroid Administration in Pediatric Intestinal Transplant Recipients,” Transplantation 108 (2024): e202-e203.

[16] A. Hamad, H. Aziz, I. R. Kamel, D. A. Diaz, and T. M. Pawlik, “Yttrium-90 Radioembolization: Current Indications and Outcomes,” Journal of Gastrointestinal Surgery 27 (2023): 604-614.

[17] X. He, J. Sun, J. Zhuang, H. Xu, Y. Liu, and D. Wu, “Microneedle System for Transdermal Drug and Vaccine Delivery: Devices, Safety, and Prospects,” Dose Response 17 (2019): 1559325819878585.

[18] M. Starlin Chellathurai, S. Mahmood, Z. Mohamed Sofian, et al., “Biodegradable Polymeric Insulin Microneedles—a Design and Materials Perspective Review,” Drug Delivery 31 (2024): 2296350.

[19] R. S. Ingrole, E. Azizoglu, M. Dul, J. C. Birchall, H. S. Gill, and M. R. Prausnitz, “Trends of Microneedle Technology in the Scientific Literature, Patents, Clinical Trials and Internet Activity,” Biomaterials 267 (2021): 120491.

[20] M. Razavi, J. Wang, and A. S. Thakor, “Localized Drug Delivery Graphene Bioscaffolds for Cotransplantation of Islets and Mesenchymal Stem Cells,” Science Advances 7 (2021): eabf9221.

[21] M. Razavi, “A Collagen Based Cryogel Bioscaffold That Generates Oxygen for Islet Transplantation,” Advanced Functional Materials 30, no. 15 (2020): 1902463.

[22] F. Corduas, D. A. Lamprou, and E. Mancuso, “Next-generation Surgical Meshes for Drug Delivery and Tissue Engineering Applications: Materials, Design and Emerging Manufacturing Technologies,” Bio-Design and Manufacturing 4 (2021): 278-310.

[23] N. Montenegro-Navarro, C. García-Báez, and M. García-Caballero, “Molecular and Metabolic Orchestration of the Lymphatic Vasculature in Physiology and Pathology,” Nature Communications 14 (2023): 8389.

[24] D. Fan, E. E. Creemers, and Z. Kassiri, “Matrix as an Interstitial Transport System,” Circulation Research 114 (2014): 889-902.

[25] L. Claesson-Welsh, E. Dejana, and D. M. McDonald, “Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies,” Trends in Molecular Medicine 27 (2021): 314-331.

[26] J. H. Kim, H. Jeong, Y. Choo, et al., “Optimizing Mannitol Use in Managing Increased Intracranial Pressure: A Comprehensive Review of Recent Research and Clinical Experiences,” Korean Journal of Neurotrauma 19 (2023): 162-176.

[27] N. D. Doolittle, L. L. Muldoon, A. Y. Culp, and E. A. Neuwelt, “Delivery of Chemotherapeutics Across the Blood-brain Barrier: Challenges and Advances,” Advances in Pharmacology 71 (2014): 203-243.

[28] S. Chen, A. Nazeri, H. Baek, et al., “A Review of Bioeffects Induced by Focused Ultrasound Combined With Microbubbles on the Neurovascular Unit,” Journal of Cerebral Blood Flow and Metabolism 42 (2022): 3-26.

[29] Y. Han, J. Sun, H. Wei, J. Hao, W. Liu, and X. Wang, “Ultrasound-Targeted Microbubble Destruction: Modulation in the Tumor Microenvironment and Application in Tumor Immunotherapy,” Frontiers in immunology 13 (2022): 937344.

[30] P. G. Durham, A. Butnariu, R. Alghorazi, G. Pinton, V. Krishna, and P. A. Dayton, “Current Clinical Investigations of Focused Ultrasound Blood-brain Barrier Disruption: A Review,” Neurotherapeutics 21 (2024): e00352.

[31] R. S. Vaseem, A. D'cruz, S. Shetty, et al., “Transdermal Drug Delivery Systems: A Focused Review of the Physical Methods of Permeation Enhancement,” Advanced Pharmaceutical Bulletin 14 (2024): 67-85.

[32] J. D. Byrne, J. J. Yeh, and J. M. DeSimone, “Use of Iontophoresis for the Treatment of Cancer,” Journal of Controlled Release 284 (2018): 144-151.

[33] E. Harris and J. J. Elmer, “Optimization of Electroporation and Other Non-viral Gene Delivery Strategies for T Cells,” Biotechnology Progress 37 (2021): e3066.

[34] A. Muralidharan and P. E. Boukany, “Electrotransfer for Nucleic Acid and Protein Delivery,” Trends in Biotechnology (2023).

[35] J. C. D. S. Luz, F. Antunes, M. A. Clavijo-Salomon, et al., “Clinical Applications and Immunological Aspects of Electroporation-Based Therapies,” Vaccines (Basel) (2021): 9.

[36] E. Eugenin, E. Camporesi, and C. Peracchia, “Direct Cell-Cell Communication via Membrane Pores, Gap Junction Channels, and Tunneling Nanotubes: Medical Relevance of Mitochondrial Exchange,” International Journal of Molecular Sciences (2022): 23.

[37] C. Pathak, F. U. Vaidya, B. N. Waghela, et al., “Insights of Endocytosis Signaling in Health and Disease,” International Journal of Molecular Sciences (2023): 24.

[38] J. Lu, T. Wu, B. Zhang, et al., “Types of Nuclear Localization Signals and Mechanisms of Protein Import Into the Nucleus,” Cell Communication and Signaling 19 (2021): 60.

[39] C. H. Heldin, B. Lu, R. Evans, and J. S. Gutkind, “Signals and Receptors,” Cold Spring Harbor perspectives in biology 8 (2016): a005900.

[40] D. D. Liu, M. Ullah, W. Concepcion, J. J. Dahl, and A. S. Thakor, “The Role of Ultrasound in Enhancing Mesenchymal Stromal Cell-based Therapies,” Stem Cells Translational Medicine 9 (2020): 850-866.

[41] N. D. C. Noronha, A. Mizukami, C. Caliári-Oliveira, et al., “Priming Approaches to Improve the Efficacy of Mesenchymal Stromal Cell-based Therapies,” Stem Cell Research & Therapy 10 (2019): 131.

[42] J. Ma, Y. Mo, M. Tang, et al., “Bispecific Antibodies: From Research to Clinical Application,” Frontiers in immunology 12 (2021): 626616.

[43] A. C. Marques, P. C. Costa, S. Velho, and M. H. Amaral, “Lipid Nanoparticles Functionalized With Antibodies for Anticancer Drug Therapy,” Pharmaceutics (2023): 15.

[44] H. Derakhshankhah and S. Jafari, “Cell Penetrating Peptides: A Concise Review With Emphasis on Biomedical Applications,” Biomedicine & Pharmacotherapy 108 (2018): 1090-1096.

[45] Z. He, K. Men, Z. Qin, Y. Yang, T. Xu, and Y. Wei, “Non-viral and Viral Delivery Systems for CRISPR-Cas9 Technology in the Biomedical Field,” Science China Life Sciences 60 (2017): 458-467.

[46] A. S. Thakor and S. S. Gambhir, “Nanooncology: The Future of Cancer Diagnosis and Therapy,” CA: A Cancer Journal for Clinicians 63 (2013): 395-418.

[47] A. R. Rezai, P. D'Haese, V. Finomore, et al., “Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease,” New England Journal of Medicine 390 (2024): 55-62.

[48] J. Ruan, Y. Shi, P. Luo, et al., “Safety and Feasibility of Intra-arterial Delivery of Teniposide to High Grade Gliomas After Blood-brain Barrier Disruption: A Case Series,” J NeuroInterventional Surgery 16 (2024): 1152-1156.

[49] J. R. Eisenbrey, F. Forsberg, C. E. Wessner, et al., “US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial,” Radiology 298 (2021): 450-457.

[50] A. Elsakka, B. J. Park, B. Marinelli, N. C. Swinburne, and J. Schefflein, “Virtual and Augmented Reality in Interventional Radiology: Current Applications, Challenges, and Future Directions,” Techniques in Vascular and Interventional Radiology 26 (2023): 100919.

[51] E. Katsoulakis, Q. Wang, H. Wu, et al., “Digital Twins for Health: A Scoping Review,” NPJ Digital Medicine 7 (2024): 77.

[52] J. N. Albertini, L. Derycke, A. Millon, and R. Soler, “Digital Twin and Artificial Intelligence Technologies for Predictive Planning of Endovascular Procedures,” Seminars in Vascular Surgery 37 (2024): 306-313.

[53] A. Amin, S. A. Cardoso, J. Suyambu, et al., “Future of Artificial Intelligence in Surgery: A Narrative Review,” Cureus 16 (2024): e51631.

[54] G. A. McLeod, “Novel Approaches to Needle Tracking and Visualisation,” Anaesthesia 76 Suppl 1 (2021): 160-170.

[55] L. Scolaro, D. Lorenser, W. Madore, et al., “Molecular Imaging Needles: Dual-modality Optical Coherence Tomography and Fluorescence Imaging of Labeled Antibodies Deep in Tissue,” Biomedical Optics Express 6 (2015): 1767-1781.

[56] Y. Rivero-Moreno, S. Echevarria, C. Vidal-Valderrama, et al., “Robotic Surgery: A Comprehensive Review of the Literature and Current Trends,” Cureus 15 (2023): e42370.

[57] J. E. Knudsen, U. Ghaffar, R. Ma, and A. J. Hung, “Clinical Applications of Artificial Intelligence in Robotic Surgery,” Journal of Robotic Surgery 18 (2024): 102.

[58] G. Najafi, K. Kreiser, M. Abdelaziz, and M. S. Hamady, “Current State of Robotics in Interventional Radiology,” Cardiovascular and Interventional Radiology 46 (2023): 549-561.

[59] N. Kauffman, J. Morrison, K. O'Brien, J. Fan, and K. R. Zinn, “Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics,” Pharmaceutics (2023): 15.

[60] M. Widel, “Radionuclides in Radiation-induced Bystander Effect; May It Share in Radionuclide Therapy?,” Neoplasma 64 (2017): 641-654.

[61] J. Liu, H. Cabral, B. Song, et al., “Nanoprobe-Based Magnetic Resonance Imaging of Hypoxia Predicts Responses to Radiotherapy, Immunotherapy, and Sensitizing Treatments in Pancreatic Tumors,” ACS Nano 15 (2021): 13526-13538.

[62] Q. Zhao, Y. Chen, W. Huang, H. Zhou, and W. Zhang, “Drug-microbiota Interactions: An Emerging Priority for Precision Medicine,” Signal Transduction and Targeted Therapy 8 (2023): 386.

[63] P. M. Glassman, J. W. Myerson, L. T. Ferguson, et al., “Targeting Drug Delivery in the Vascular System: Focus on Endothelium,” Advanced Drug Delivery Reviews 157 (2020): 96-117.

[64] C. Reighard, S. Junaid, and W. M. Jackson, et al., “Anesthetic Exposure during Childhood and Neurodevelopmental Outcomes: A Systematic Review and Meta-analysis,” JAMA Network Open 5 (2022): e2217427.

[65] E. C. Whipple, C. A. Favero, and N. F. Kassell, “Focused Ultrasound in Neuro-oncology: The Role of the Focused Ultrasound Foundation in Driving Adoption and Innovation,” Journal of Neuro-Oncology 156 (2022): 11-13.

[66] R. Kochhar, “Intralesional Steroid Injection Therapy in the Management of Resistant Gastrointestinal Strictures,” World Journal of Gastrointestinal Endoscopy 2 (2010): 61-68.

[67] M. H. Amer, F. Rose, K. M. Shakesheff, M. Modo, and L. J. White, “Translational Considerations in Injectable Cell-based Therapeutics for Neurological Applications: Concepts, Progress and Challenges,” NPJ Regenerative Medicine 2 (2017): 23.

[68] J. K. Elrod, “The Hub-and-spoke Organization Design: An Avenue for Serving Patients Well,” BMC Health Services Research [Electronic Resource] 17 (2017): 457.

[69] I. Ford and J. Norrie, “Pragmatic Trials,” New England Journal of Medicine 375 (2016): 454-463.

[70] G. Shi, Y. Cui, J. Zhao, et al., “Identifying TOPK and Hypoxia Hallmarks in Esophageal Tumors for Photodynamic/Chemo/Immunotherapy and Liver Metastasis Inhibition With Nanocarriers,” ACS Nano 17 (2023): 6193-6207.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.